https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24833 A, del5395, I157T), NBS1 (657del5) and PALB2 (509-510delGA, 172-175delTTGT). A statistically significant association between the 657del5 mutation and an increased risk of pancreatic cancer was observed for NBS1 gene. The Slavic NBS1 gene mutation (657delACAAA) was detected in 8 of 383 (2.09%) unselected cases compared with 22 of 4,000 (0.55%) controls (OR: 3.80, p = 0.002). The PALB2 509_510delGA and 172-175delTTGT mutations combined were seen in 2 (0.52%) unselected cases of PaCa and in 8 (0.20%) of 4,000 controls (OR: 2.61, p = 0.49). For BRCA1, the three mutations combined were detected in 4 of 383 (1.04%) PaCa patients and in 17 of 4,000 (0.42%) controls (OR: 2.46, p = 0.20). CHEK2 mutations were not associated with the risk of pancreatic cancer (OR: 1.11, p = 0.72). The founder mutation in NBS1 (657del5) was associated with an increased risk of PaCa in heterozygous carriers, indicating that this mutation appears to predispose to cancer of the pancreas. By identifying pancreatic cancer risk groups, founder mutation testing in Poland should be considered for people at risk for PaCa.]]> Wed 24 Nov 2021 15:53:13 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27601 Wed 11 Apr 2018 15:11:09 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:4382 G, 4154delA) including 127 ovarian cases and 127 unaffected controls who had both breasts and ovaries intact. Controls were matched to cases by year of birth and BRCA1 mutation. Genotyping analysis was performed using PCR-based restriction fragment length polymorphism analysis. Odds ratios (OR) were calculated using conditional and penalized univariable and multivariable logistic regression. Results: A comparison of the genotype frequencies between cases and controls revealed no association of the PHB 3'UTR _CT+TT genotypes with ovarian cancer risk (ORadj 1.34; 95% CI, 0.59–3.11). Conclusion: Our data suggest that the PHB 3'UTR polymorphism does not modify ovarian cancer risk in women carrying one of the three Polish BRCA1 founder mutations.]]> Wed 11 Apr 2018 14:48:22 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10390 Wed 11 Apr 2018 12:49:05 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46235 Tue 15 Nov 2022 08:51:17 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35067 853.0–973.9 μg/l). Among five analyzed genetic variants, rs11568818 in MMP-7 appeared to be correlated with 2-fold increased prostate cancer risk (OR = 2.39, 95% CI = 1.19–4.82, p = 0.015). Conclusion: Our results suggest a significant correlation of higher serum zinc levels with the diagnosis of prostate cancer. The polymorphism rs11568818 in MMP-7 gene was also associated with an increased prostate cancer risk in Poland.]]> Thu 04 Nov 2021 10:38:46 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7576 Sat 24 Mar 2018 08:37:24 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:9541 Sat 24 Mar 2018 08:35:48 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:11144 Sat 24 Mar 2018 08:08:29 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:5178 g), a novel intronic change IVS1+36 g>c and two common variants A148T and IVS3+29 c>g. The results of this study revealed a paucity of mutations in CDKN2A/ARF suggesting that in the Polish population this gene does not contribute significantly to early-onset breast cancer, pancreatic cancer and malignant melanoma.]]> Sat 24 Mar 2018 07:47:42 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25547 Sat 24 Mar 2018 07:26:05 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:4736 T polymorphism in the VEGF gene and its association with sporadic breast cancer risk has been analyzed in various studies yielding conflicting results. To analyze the role of this polymorphism in modifying hereditary breast and ovarian cancer risks, we conducted a case-control study and genotyped 755 Polish BRCA1 carriers, including 319 breast cancer cases, 146 ovarian cancer cases, and 290 unaffected controls. The results revealed an association of the CT + TT genotypes with a reduced breast cancer risk (ORadj 0.63, 95% CI, 0.41-0.98; ORclustered 0.63, 95% CI, 0.48-0.83), and a potential effect on ovarian cancer risk (ORadj 0.62, 95% CI, 0.33-1.18; ORclustered 0.62, 95% CI, 0.47-0.83). Thus, the 936_C>T polymorphism appears to modify disease risks in BRCA1 carriers.]]> Sat 24 Mar 2018 07:21:09 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49791 Fri 02 Jun 2023 17:14:07 AEST ]]>